{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:07:28Z","timestamp":1791310048184,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd010410","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T00:00:00Z","timestamp":1392940800000}}],"reference-count":29,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010410.pub2","type":"journal-article","created":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T04:29:13Z","timestamp":1392956953000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Low dose naltrexone for induction of remission in Crohn's disease"],"prefix":"10.1002","author":[{"given":"Dan","family":"Segal","sequence":"first","affiliation":[{"name":"London Health Sciences Centre - University Hospital; 339 Windermere Road London Ontario Canada N6A 5A5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London Ontario Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Chande","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre - Victoria Hospital; Room E6-321A 800 Commissioners Road East London Ontario Canada N6A 5W9"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,21]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD010410.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","article-title":"Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial","volume":"56","author":"Smith","year":"2011","journal-title":"Digestive Diseases and Sciences"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010410.pub2-BIB0002|cit2","first-page":"S85","article-title":"Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo-controlled trial","volume":"138","author":"Smith","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD010410.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCG.0b013e3182702f2b","article-title":"Safety and Tolerability of Low-dose Naltrexone Therapy in Children With Moderate to Severe Crohn's Disease: A Pilot Study","volume":"47","author":"Smith","year":"2013","journal-title":"Journal of clinical gastroenterology"},{"key":"10.1002\/14651858.CD010410.pub2-BIB0004|cit4","unstructured":"NCT01810185 Low dose naltrexone in symptomatic inflammatory bowel disease http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01810185"},{"issue":"21","key":"10.1002\/14651858.CD010410.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10.1002\/14651858.CD010410.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"issue":"9573","key":"10.1002\/14651858.CD010410.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD010410.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/gut.2010.234617","article-title":"Surgery for adult Crohn's disease: what is the actual risk?","volume":"60","author":"Bouguen","year":"2011","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD010410.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2011.02.045","article-title":"Conventional medical management of inflammatory bowel disease","volume":"140","author":"Burger","year":"2011","journal-title":"Gastroenterology"},{"issue":"7109","key":"10.1002\/14651858.CD010410.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD010410.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2982.2007.00944.x","article-title":"Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial","volume":"19","author":"Foxx-Orenstein","year":"2007","journal-title":"Neurogastroenterology and Motility"},{"issue":"7650","key":"10.1002\/14651858.CD010410.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010410.pub2-BIB0013|cit13","article-title":"Chapter 7: Selecting studies and collecting data","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010410.pub2-BIB0014|cit14","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook of Systematic Review of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"1-3","key":"10.1002\/14651858.CD010410.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.regpep.2009.03.012","article-title":"Opioid receptors in the gastrointestinal tract","volume":"155","author":"Holzer","year":"2009","journal-title":"Regulatory Peptides"},{"key":"10.1002\/14651858.CD010410.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1016\/S1873-9946(12)60502-9","article-title":"Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life","volume":"6 Suppl 2","author":"Hommes","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"4","key":"10.1002\/14651858.CD010410.pub2-BIB0017|cit17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001333.pub4","article-title":"Oral naltrexone maintenance treatment for opioid dependence","author":"Minozzi","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010410.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"46-54.e42; quiz","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD010410.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/gut.33.3.331","article-title":"Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms","volume":"33","author":"Olaison","year":"1992","journal-title":"Gut"},{"issue":"8","key":"10.1002\/14651858.CD010410.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD010410.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1172\/JCI200316750","article-title":"Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation","volume":"111","author":"Philippe","year":"2003","journal-title":"Journal of Clinical Investigation"},{"issue":"6","key":"10.1002\/14651858.CD010410.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/gut.2005.080887","article-title":"Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation","volume":"55","author":"Philippe","year":"2006","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD010410.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0022-3565(25)10212-7","article-title":"Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers","volume":"264","author":"Preston","year":"1993","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD010410.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gut.25.6.665","article-title":"Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery","volume":"25","author":"Rutgeerts","year":"1984","journal-title":"Gut"},{"key":"10.1002\/14651858.CD010410.pub2-BIB0025|cit25","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Sch\u00fcnemann","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD010410.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","article-title":"Low-dose naltrexone therapy improves active Crohn's disease","volume":"102","author":"Smith","year":"2007","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD010410.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1055\/s-2007-1018188","article-title":"Endoscopic lesions in Crohn's disease early after ileocecal resection","volume":"20","author":"Tytgat","year":"1988","journal-title":"Endoscopy"},{"issue":"1-2","key":"10.1002\/14651858.CD010410.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0006-8993(89)91562-X","article-title":"Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors","volume":"480","author":"Zagon","year":"1989","journal-title":"Brain Research"},{"issue":"5","key":"10.1002\/14651858.CD010410.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/egh.11.62","article-title":"Targeting opioid signaling in Crohn's disease: new therapeutic pathways","volume":"5","author":"Zagon","year":"2011","journal-title":"Expert Review of Gastroenterology and Hepatology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010410.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010410.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T22:12:01Z","timestamp":1746137521000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010410.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,21]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010410.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD010410.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,21]]}}}